Transparency

Disclosure of Transfers of Value

Transparency is the prerequisite for building trust with the public and the patients. Therefore, from July 2017, Mylan and the legal entities Mylan UK Healthcare Limited, Generics UK Limited and MEDA Pharmaceuticals Limited (UK) will disclose the monetary benefits between these entities and the players in the healthcare sector.

2019 Reports:

Methodological Note_MfE_UK_2019

Mylan UK Healthcare Limited:
Mylan UK Healthcare Limited HCO Reports 2019
Mylan UK Healthcare Limited Meetings and Site Visits Disclosure 2019
Mylan UK Healthcare Limited Fees for Services Report 2019
Mylan UK Healthcare Limited PO Reports 2019

2018 Reports:

Methodological Note_MfE_UK_2018

Mylan UK Healthcare Limited:
Mylan UK Healthcare Limited HCO Reports 2018
Mylan UK Healthcare Limited Meetings and Site Visits Disclosure 2018
Mylan UK Healthcare Limited Fees for Services Report 2018
Mylan UK Healthcare Limited PO Reports 2018

2017 Reports:

Methodological Note MfE UK 2017

Mylan UK Healthcare Limited:
UK Mylan UK Healthcare Limited HCO Reports 2017
UK Mylan UK Healthcare Limited Events Reports 2017
UK Mylan UK Healthcare Limited Fees for Services Reports 2017
UK Mylan UK Healthcare Limited PO Reports 2017

Generics UK Ltd:
UK Generics [U.K.] Ltd HCO Report 2017
UK Generics [U.K.] Ltd Fees Event Disclosure Report 2017
UK Generics [U.K.] Ltd Fees for Service and Consultancy Report 2017
UK Generics [U.K.] Ltd PO Report Report 2017

MEDA Pharmaceuticals Ltd (UK):
UK Meda Pharmaceutical Company HCO Report 2017
UK Meda Pharmaceutical Company Fees Event Disclosure Report 2017
UK Meda Pharmaceutical Company Fees for Services 2017
UK Meda Pharmaceutical Company PO Report 2017